REcanalization of Distal Cerebral Vessels In Acute Stroke Using ApeRio (REVISAR)

Area of Science:

• Neurology
• Interventional Neurology
• Medical Devices

Background:

• Mechanical thrombectomy (MT) has shown mixed results for medium vessel occlusions (MeVOs).
• Further investigation into dedicated small devices for MeVO treatment is warranted.
• This study evaluates the APERIO Hybrid as a primary device for MeVO stroke.

Purpose of the Study:

• To assess the efficacy and safety of the APERIO Hybrid device for first-line mechanical thrombectomy in MeVO patients.
• To determine the recanalization rates and clinical outcomes following MT with the APERIO Hybrid.
• To evaluate the safety profile, including symptomatic intracranial hemorrhage (ICH), associated with the APERIO Hybrid device.

Main Methods:

• A prospective, multicenter registry study included 134 MeVO patients treated with APERIO or APERIO Hybrid.
• The primary endpoint was successful recanalization (TICI 2b/3) within three passes without rescue techniques or symptomatic ICH.
• Outcomes included recanalization rates, modified Rankin Scale (mRS) scores at 90 days, and incidence of ICH and subarachnoid hemorrhage.

Main Results:

• The primary endpoint was achieved in 81.5% of patients (95% CI 74.5% to 88.5%).
• Overall recanalization success (TICI 2b/3) was 95.8%, with high rates achieved on the first pass using APERIO Hybrid.
• Functional independence (mRS 0-2 at 90 days) was achieved by 79.0% of patients, with no symptomatic ICH reported.

Conclusions:

• The APERIO and APERIO Hybrid devices are safe and effective as first-line treatments for MT in MeVO stroke.
• High rates of successful recanalization were observed across multiple stroke centers.
• These devices represent a valuable option for managing MeVO stroke patients.